tbuckley/cabot-search huggingface dataset:
Effect of Tamoxifen on Sexual Functioning in Patients With Breast Cancer
Authors: Joanne E. Mortimer, Leslie Boucher, Jack Baty, Diana L. Knapp, Elizabeth Ryan, Julia H. Rowland
Journal: Journal of Clinical Oncology (1999)

PURPOSE: To define the incidence of sexual dysfunction in a population of women with breast cancer treated with tamoxifen. PATIENTS AND METHODS: Breast cancer patients with a performance status of 0 to 2 who had been treated with tamoxifen for 2 to 24 months completed the following measures: the Center for Epidemiologic Studies–Depression Scale, the Sexual History Form, and the Breast Cancer Prevention Trial Symptom Checklist. Forty-nine of the participants underwent gynecologic examinations with vaginal smears for determination of estrogen effect. RESULTS: Fifty-seven women were entered onto the trial. Sexual desire, arousal, and ability to achieve orgasm were comparable to norms established in participants in the Tamoxifen Prevention Trial (National Surgical Adjuvant Breast and Bowel Project P-01). Pain, burning, or discomfort with intercourse was reported in 54% of patients and did not correlate with age, surgical treatment of the primary cancer, or chemotherapy. Estrogen effect was seen on the vaginal smears of 34 of 49 participants and was more common in older patients (P = .054). The presence of estrogen effect correlated with negative reactions during sex (P = .02) and vaginal dryness or tightness (P = .046). CONCLUSION: Women treated with tamoxifen in the adjuvant setting experienced symptoms of sexual dysfunction. The individual contributions of chemotherapy and tamoxifen to sexual dysfunction warrant prospective study.
Treatment of hairy cell leukemia with alternating cycles of pentostatin and recombinant leukocyte A interferon: results of a phase II study.
Authors: A Martin, S Nerenstone, W J Urba, D L Longo, J B Lawrence, J W Clark, M J Hawkins, S P Creekmore, J W Smith, R G Steis
Journal: Journal of Clinical Oncology (1990)

Fifteen patients with hairy cell leukemia (HCL) were treated with deoxycoformycin (pentostatin; dCF) (4 mg/m2 intravenous [IV] every week x 3) and recombinant interferon-alpha 2a (rIFN-alpha 2a) (3 x 10(6) units subcutaneously [SC] daily x 4 weeks) in alternating months for a total of 14 months. Eleven patients had undergone splenectomy; four had received prior systemic therapy with chlorambucil and/or steroids. All 15 are evaluable for toxicity and peripheral blood response, while 14 are assessable for bone marrow response. Toxicity was tolerable with grade 3 or 4 nausea and vomiting in three patients, neutropenic fevers in five, transient but significant depression in eight, and localized cutaneous herpes zoster in four. Circulating hairy cells were undetectable by the end of the first month in 10 of 13 patients, and by the end of the second month in the other three. Fourteen patients had bilateral bone marrow biopsies performed at baseline after 6 months of treatment, at the end of treatment (14 months), and at 6-month intervals during follow-up. Before treatment, all patients had hypercellular marrows with hairy cels replacing normal marrow elements; all showed at least a 95% clearing of their hairy cell infiltrate by 6 months of therapy. However, small collections of residual hairy cells could be detected intermittently on at least one side of bilateral samples in all patients. All patients have completed treatment with a median duration of follow-up off therapy of 27 months (range, 15 to 31 months). To date, all peripheral counts and serum soluble interleukin-2 receptor (sIL2R) levels remain stable, and no patient has had progression of the hairy cell infiltrate in the bone marrow. Although no patient achieved a pathologic complete response, alternating monthly cycles of dCF and rIFN-alpha 2a produced durable partial remissions (PRs) in all patients. Continued follow-up is required to determine the length of such remissions.
Sperm selection in natural conception: what can we learn from Mother Nature to improve assisted reproduction outcomes?
Authors: Denny Sakkas, Mythili Ramalingam, Nicolas Garrido, Christopher L.R. Barratt
Journal: Human Reproduction Update (2015)

In natural conception only a few sperm cells reach the ampulla or the site of fertilization. This population is a selected group of cells since only motile cells can pass through cervical mucus and gain initial entry into the female reproductive tract. In animals, some studies indicate that the sperm selected by the reproductive tract and recovered from the uterus and the oviducts have higher fertilization rates but this is not a universal finding. Some species show less discrimination in sperm selection and abnormal sperm do arrive at the oviduct. In contrast, assisted reproductive technologies (ART) utilize a more random sperm population. In this review we contrast the journey of the spermatozoon in vivo and in vitro and discuss this in the context of developing new sperm preparation and selection techniques for ART. A review of the literature examining characteristics of the spermatozoa selected in vivo is compared with recent developments in in vitro selection and preparation methods. Contrasts and similarities are presented. New technologies are being developed to aid in the diagnosis, preparation and selection of spermatozoa in ART. To date progress has been frustrating and these methods have provided variable benefits in improving outcomes after ART. It is more likely that examining the mechanisms enforced by nature will provide valuable information in regard to sperm selection and preparation techniques in vitro. Identifying the properties of those spermatozoa which do reach the oviduct will also be important for the development of more effective tests of semen quality. In this review we examine the value of sperm selection to see how much guidance for ART can be gleaned from the natural selection processes in vivo.
P-050 The role of radiotherapy or chemoradiotherapy for oligo-recurrence of esophageal cancer after curative resection or chemoradiotherapy
Authors: T. Matsumoto, T. Nishina, T. Kajiwara, K. Uwazu, A. Nishikawa, Y. Niibe, M. Kataoka
Journal: Annals of Oncology (2015)
Effectiveness of an online insomnia program (SHUTi) for prevention of depressive episodes (the GoodNight Study): a randomised controlled trial
Authors: Helen Christensen, Philip J Batterham, John A Gosling, Lee M Ritterband, Kathleen M Griffiths, Frances P Thorndike, Nick Glozier, Bridianne O'Dea, Ian B Hickie, Andrew J Mackinnon
Journal: The Lancet Psychiatry (2016)
Treatment of convulsive status epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer-specific survival following radical prostatectomy or radiation therapy and short course hormonal therapy in men with localized, unfavorable-risk prostate cancer
Authors: H. K. Tsai, M. Chen, D. G. McLeod, P. R. Carroll, J. P. Richie, A. V. D’Amico
Journal: Journal of Clinical Oncology (2006)

4572 Background: We estimated prostate cancer-specific mortality (PCSM) rates following radical prostatectomy (RP) or external beam radiation therapy (RT) and 6 months of androgen suppression therapy (AST) in men with unfavorable-risk prostate cancer. Methods: Between 1981 and 2002, 3,240 men with intermediate- (T2b or Gleason score 7 or prostate-specific antigen (PSA) &gt; 10 to 20 ng/mL) or high-risk (T2c or Gleason score 8 to 10 or PSA &gt; 20 ng/mL) prostate cancer were treated with RP (n = 2,690) or RT+AST (n = 550) and comprised the study cohort. If PSA failure occurred, defined by a postoperative PSA level &gt; 0.2 ng/mL and rising or by the ASTRO definition following RT+AST, then men received salvage RT or life-long AST, respectively. Life-long AST was initiated if PSA failure occurred after salvage RT. Imaging of the pelvis and skeleton was negative for metastases at the time of any salvage therapy. Gray’s formulation was used to compare the cumulative incidence estimates of PCSM and to calculate the adjusted hazard ratios (HR) and associated 95% confidence intervals for initial treatment and known prognostic factors. Results: After a median follow-up time for living patients of 4.5 and 4.2 years for the RP and RT+AST cohorts, respectively, there were no significant differences in the estimates of PCSM following RP or RT+AST in men with intermediate- (p = 0.44) or high-risk (p = 0.26) disease. As shown in the Table , after adjusting for PSA level, Gleason score, and T-category, initial therapy was not significantly associated with PCSM for men with intermediate- (HR: 1.2 [95% CI: 0.3, 4.3]; p = 0.78) or high-risk (HR: 1.2 [95% CI: 0.5, 2.8]; p = 0.62) disease. Conclusion: Men with localized, unfavorable-risk prostate cancer who receive RT and short course AST as initial therapy appear to have similar PCSM rates as men who undergo initial RP followed by salvage RT and life-long AST after first and second PSA failure, respectively. [Table: see text] No significant financial relationships to disclose.
연구논문 : 단일 센터에서 진단된 간내담관암종 318예의 생존율 및 생존율에 영향을 미치는 인자들에 대한 분석
Authors: 송기원 ( Gi Won Song ), 이승규 ( Sung Gyu Lee ), 이영주 ( Young Joo Lee ), 박광민 ( Kwang Min Park ), 황신 ( Shin Hwang ), 김기훈 ( Ki Hun Kim ), 안철수 ( Chul Soo Ahn ), 문덕복 ( Deok Bog Moon ), 하태용 ( Tae Yong Ha ), 정동환 ( Dong Hwan Jung )
Journal: Clinical and Molecular Hepatology (2007)
Relationship between efficacy of denileukin diftitox (Dd) and antibody development in cutaneous T-cell lymphoma (CTCL): An analysis of two phase III studies
Authors: M. Acosta, M. Duvic, A. Lopez-Anaya
Journal: Journal of Clinical Oncology (2009)

e19534 Background: Dd is a novel IL-2 receptor-targeted recombinant fusion protein approved for persistent/recurrent CTCL expressing CD25. The effect of antibody titers on efficacy in CTCL was assessed in 2 phase III studies (11 &amp; 14). Methods: Dd doses were 9 or 18 mcg/kg daily for 5 days, repeating every 21 days, up to 8 courses. Serum samples were collected prior to Dd infusion on day 1 of courses 1, 3, 5, and 7. Immune response to Dd was assessed using 2 enzyme-linked immunoassays: 1 for anti-IL-2 antibody (Ab) and the other for anti-Dd Ab. Immunogenicity data reflect percentage of subjects whose test results were considered positive for antibody to the intact Dd fusion protein. Results: In Study 11, 66% of subjects tested positive for anti-Dd Ab at baseline, possibly due to prior exposure to diphtheria toxin or its vaccine. In both studies, and for both doses, rapid increases in Ab titers were observed in nearly 100% of subjects from courses 1 to 3 (∼650-fold, 11; &gt;=625-fold, 14). After 3 treatment courses, mean Ab levels stabilized and did not change appreciably with time. Pharmacokinetic (PK) parameters (Cmax and AUC) decreased substantially during the same period, but no relationship between Ab formation and clearance was identified. Low Spearman Correlation coefficient values indicated lack of a significant association (i) between the pre-treatment or treatment-related Ab levels and (ii) between PK changes for subjects who responded and subjects who did not respond. Of subjects positive for Ab at baseline, 43% (27/63) and 38% (13/34) responded to treatment, as compared to 50% (16/32) and 54% (7/13) for subjects who had no detectable Ab at baseline in Studies 11 and 14 respectively. There appeared to be higher incidences of response in subjects with lower initial Ab titers. Conclusions: In the studies analyzed, antibody formation in response to Dd exposure did not appear to compromise efficacy for treatment of CTCL. [Table: see text]
Immature myeloid cell (ImC)- mediated immunosuppression in advanced renal cell cancer (RCC)
Authors: H. R. Kuebler, J. Dannull, T. Y. Tseng, A. Zhang, Z. Su, P. Dahm, J. Vieweg
Journal: Journal of Clinical Oncology (2006)

10042 Background: RCC affects the immunsystem by inhibiting the process of differentiation of antigen-resenting cells from their myeloid precursors by secreting tumor-derived factors such as VEGF. ImC induce a profound state of immune suppression that foster tumor tolerance by inhibition of tumor specific T cells. In this study, we asked whether increased ImC frequencies can be found in peripheral blood from RCC patients and if ImC frequencies correlated positively with increased levels of tumor-derived serum markers. Methods: ImC frequencies from healthy volunteers and RCC patients were determined by FACS. ImC were isolated by magnetic bead separation techniques and their immunosuppressive activity was determined in IFN-γ ELISPOT analyses, CTL and T-cell proliferation assays. The production of reactive oxygen species by ImC was analyzed utilizing specific probes and inhibitors. Tumor-derived serum markers were quantified by ELISA, enzyme immune assays and cytometric bead arrays. Microarray analyses were performed to identify novel, highly specific ImC markers. Results: RCC patients demonstrate higher ImC frequencies (0.8 - 3.2% of total PBMC) compared to healthy donors. The increased ImC frequencies are positively correlated with serum levels of VEGF, PGE-2, IL-13 and M-CSF in RCC patients and the concentration of byproducts of oxidative burst, including iso-prostane and malondialdehyde, was significantly enhanced. Isolated ImC exhibited profound immunosuppressive effects on CTL and CD4+ T cell response in an antigen specific fashion. Immunosuppression by ImC was mediated by release of ROS, including peroxide and superoxide anions and by generation of nitric oxide radicals as evidenced in functional assays. Results from microarray analyses reveal EP-1, EphA5, and PEX-5 as novel ImC markers. Conclusions: These data suggest that RCC may induce the development of immunosuppressive ImC population through secretion of cytokines such as VEGF, IL-13, M-CSF and PGE-2. Inhibition of specific cytokine activity or the use of differentiating agents may represent strategies to decrease immunosuppressive ImC population. Results from a phase I clinical trial investigating the effects of all-trans retinoic acid (ATRA) on differentiation of ImC in RCC patients will be presented. No significant financial relationships to disclose.
Role of Macrophages in the Tumor-Induced Suppression of Mitogen Responses in Rats
Authors: Ada M. Kruisbeek, Marita van Hees
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Role of Macrophages in the Tumor-Induced Suppression of Mitogen Responses in Rats Get access Ada M. Kruisbeek, Ada M. Kruisbeek Search for other works by this author on: Oxford Academic PubMed Google Scholar Marita van Hees Marita van Hees Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 6, June 1977, Pages 1653–1660, https://doi.org/10.1093/jnci/58.6.1653 Published: 01 June 1977 Article history Received: 14 July 1976 Accepted: 08 December 1976 Published: 01 June 1977
Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics
Authors: Najoua Lalaoui, Kay Hänggi, Gabriela Brumatti, Diep Chau, Nhu-Y.N. Nguyen, Lazaros Vasilikos, Lisanne M. Spilgies, Denise A. Heckmann, Chunyan Ma, Margherita Ghisi, Jessica M. Salmon, Geoffrey M. Matthews, Elisha de Valle, Donia M. Moujalled, Manoj B. Menon, Sukhdeep Kaur Spall, Stefan P. Glaser, Jennifer Richmond, Richard B. Lock, Stephen M. Condon, Raffi Gugasyan, Matthias Gaestel, Mark Guthridge, Ricky W. Johnstone, Lenka Munoz, Andrew Wei, Paul G. Ekert, David L. Vaux, W. Wei-Lynn Wong, John Silke
Journal: Cancer Cell (2016)
Manifestations and consequences of obstructive sleep apnoea
Authors: JH Peter, U Koehler, L Grote, T Podszus
Journal: European Respiratory Journal (1995)

Over the last two decades the diagnostic tools used in sleep medicine have developed enormously, making it possible to study the interaction of sleep-related breathing disorders (SRBD) with cardiovascular function and the autonomic nervous system, as well as the effects of SRBD on a variety of physiological processes during wakefulness. Different modes of nasal ventilation are now available, allowing all forms of SRBD to be treated. If early diagnosis and treatment are provided, the acute and long-term sequelae of SRBD can be prevented. In addition to the care and treatment of patients with severe obstructive sleep apnoea syndrome (OSAS), future patient management will need to focus on patients with milder forms of obstructive sleep apnoea (OSA). In particular, the consequences of SRBD on cardiac arrhythmias, arterial hypertension and hypersomnolence are discussed, considering epidemiological, clinical, diagnostic and therapeutic aspects. Some economical issues arising from SRBD are also discussed, and the authors conclude that a Europewide programme for early detection, treatment and prevention of SRBD is required. This could make a large contribution to the reduction of cardiovascular morbidity and mortality and also reduce the incidence of "human error catastrophes" due to hypersomnolence.
Number of metastatic sites is a strong predictor of survival in patients with non small cell lung cancer (NSCLC) brain metastases
Authors: Y. Oh, S. H. Taylor, H. Yu-Ting, M. W. Kelly, E. L. Chang, D. Suki, D. D. Karp
Journal: Journal of Clinical Oncology (2005)

7197 Background: When evaluating non small cell lung cancer (NSCLC) pts for participation in clinical protocols, two of the major determinants are staging (IIIB vs IV) and performance status, PS. Staging does not consider extent of disease or sites of metastases, and pts with central nervous system (CNS) metastases are often excluded due to presumed poor survival. Methods: To test the hypothesis that number of metastic sites affects prognosis, we analyzed 1284 cases of metastatic NSCLC presenting as new patients to MD Anderson Cancer Center from 1998 - 2002. 1060 pts had 1,2, or 3 sites of mets. Survival was analyzed utilizing tumor registry and clinic records according to presence or absence of CNS mets and by 1, 2, 3, or any number of organ sites by log-rank test. Results: 1138/1284 (88.6%) have expired. 432 had CNS mets and 706 had none at registration. For up to 2 organ sites of metastases, the presence of brain metastases gave a slightly worse survival (Table). No difference in survival was seen between patients with or without CNS mets when 3 or more organ sites of metastases were present. Survival for pts without CNS involvement correlated strongly with number of metastatic sites (p = 0.0009). As expected, CNS metastases also conferred inferior survival for all patients or those with one or two metastatic organ sites. Among patients with brain metastases as the solitary site of metastatic disease, the burden of disease measured by the number and size of metastases correlates inversely with survival. Conclusions: These data suggest that staging of NSCLC should assess the of number of metastatic sites or consider tumor burden in addition to PS and clinical stage. Furthermore, median survival for patients who present with brain metastases is only 1–2 months (12- 20%) shorter than those who do not, suggesting that systemic therapies and clinical trial options need not be curtailed in this group of patients. No significant financial relationships to disclose.
Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer
Authors: M. Knoedler, T. C. Gauler, A. Matzdorff, A. Dietz, V. Gruenwald, D. Arnold, B. Hennemann, M. Schroeder, C. Hofele, A. Schmittel, U. Keilholz
Journal: Journal of Clinical Oncology (2008)

6066 Background: Treatment options for patients with squamous cell cancer of the head and neck (SCCHN) are limited. Cetuximab, an antiepidermal growth factor receptor monoclonal antibody, and taxanes have already been used and shown clinical activity in this indication. This study assessed the efficacy and safety of cetuximab administered in combination with docetaxel in patients with Stage IIII/IV recurrent and/or metastatic SCCHN who failed on platinum-based therapy. Methods: Patients with relapse or progression after platinum therapy received cetuximab (initial dose of 400 mg/m2, followed by subsequent weekly doses of 250 mg/m2 until disease progression) and docetaxel (35 mg/m2 on days 1, 8, 15 of a 4-week cycle for a maximum of 6 cycles). The primary endpoint was the objective response rate (after cycle 2, 4, 6) according to RECIST criteria. Secondary endpoints included toxicity, time to progression and quality of life. Results: 47 patients with a median age of 59 years were enrolled within seven months across ten German sites. 45 patients were evaluable. Partial responses have been achieved in 9 (20%) patients and stable disease in 12 (27%) patients for an overall disease control rate (partial response and stable disease) of 47%. Treatment was generally tolerated without evidential overlapping toxicities. Major grade III/IV toxicities included gastric perforation (n= 1), pneumonia (n= 5), mucositis (n= 4) and skin toxicities (n= 9). Conclusions: The combination of cetuximab and docetaxel demonstrated clinically relevant efficacy in platinum-pretreated patients with SCCHN. No significant financial relationships to disclose.